By Doris Obinna
Emzor currently produces over 20 antimalarial SKUs which include: Maldox Sulfadoxine/ Pyrimethamine), Lokmal (Artemether/Lumefantrine), Piramal TS (Dihydroartemisinin/ Piperaquine), Diasunate (Artesunate/Amodiaquine), and Chloroquine, in different dosage forms including tablets, suspensions and dispersible tablets.
In commemoration of the World Malaria Day (WMD) 2025, Emzor Pharmaceutical Industries Limited, has reaffirmed its commitment to supporting both national and international efforts aimed at combating the high prevalence of malaria in Nigeria and across Sub-Saharan Africa.
Joining the rest of the global community to mark the WMD 2025, it disclosed that this year’s theme, “Malaria Ends With Us: Reinvest, Reimagine, Reignite,” closely aligns with its vision of making a tangible impact in the global fight against malaria.
Addressing journalists on Thursday, Head, Marketing and Strategy, Emzor, Mr. Kunle Faloye, said, for years, Emzor has been at the forefront of malaria prevention and treatment, producing high-quality antimalarial medications that are both accessible and affordable for millions across Africa. “Our dedication is reflected in our investment in research, development, and wide-reaching distribution networks, which have played a crucial role in reducing the malaria burden.”
To mark this year’s WMD, the firm has organised a series of impactful community outreach activities, including a health walk, free medical screenings, and the distribution of antimalarial drugs to vulnerable populations.
“Malaria continues to be a leading cause of death among pregnant women and children under five in Africa. Emzor’s long-standing initiatives in malaria control include the production of essential antimalarial drugs aimed at reducing maternal and infant mortality rates.
“Emzor currently produces over 20 antimalarial SKUs which include: Maldox Sulfadoxine/Pyrimethamine), Lokmal (Artemether/Lumefantrine), Piramal TS (Dihydroartemisinin/Piperaquine), Diasunate (Artesunate/Amodiaquine), and Chloroquine, in different dosage forms including tablets, suspensions and dispersible tablets.
“Further underscoring this commitment is Emzor’s multimillion-dollar investment in the manufacture of Active Pharmaceutical Ingredients (API), in our modern manufacturing Pharmaceutical Campus located in Sagamu, Ogun State.
“The plant will initially focus on the production of antimalarial APIs (namely Arthemeter, Lumefantrine, Sulfadoxine and Pyrimethamine). The selected APIs provide the World Health Organisation (WHO)-recommended treatment of malaria for adults and children, as well as the chemo-preventive combination therapies for malaria in both pregnant women and children under five.
“This strategic investment boosts Nigeria’s capacity to locally produce a broad range of antimalarial drugs, thereby improving access to high-quality treatments across sub-Saharan Africa. The project further underscores Emzor’s long-standing commitment to strengthening the pharmaceutical sector in the region.
“The project’s positive impact will reduce Nigeria’s dependence on imports from Asia, support GDP growth and reduce the demand of foreign exchange, and reduce the cost of production and access to these life-saving medicines by the people who need them most.”
Also, Chairman, Board of Directors, Emzor, Mr. Emeka Okoli, said: “With approximately 95 per cent of all malaria cases and 96 per cent of the deaths occurring on the continent, this is predominantly an African problem and hence, the solutions should also largely come from the continent. At Emzor, we are playing our part and pioneering the API project on the continent definitely fits into this.
“Emzor also works in partnership with local governments, NGOs, and communities to implement grassroots outreach programmes focused on education, prevention, diagnosis, and treatment. The company continues to provide subsidized and free medications to pregnant women and children, the groups most vulnerable to malaria.”
“As we mark this important day, Emzor remains steadfast in our resolve to contribute to global efforts toward malaria eradication. We will continue to innovate, collaborate, and invest in sustainable healthcare solutions that enhance lives across Nigeria and the continent,” Faloye added.